

## Lebenslauf

Name: Prof. Dr. med. Michael Helmut Riedel

Geboren: 17. Februar 1964 in Rosenheim



### Ausbildung:

- |             |   |
|-------------|---|
| 1970 - 1974 | Volksschule Planegg   |
| 1974 - 1984 | Kurt-Huber-Gymnasium, Gräfelfing  |
| 1986 - 1989 | Heilpraktikerfachschiule (Fachverband der Deutschen Heilpraktiker)  |
| 1988 - 1995 | Studium der Humanmedizin an der Ludwig-Maximilians-Universität München (LMU)  |
| 1995        | Medizinisches Staatsexamen und Teilapprobation (AiP)  |
| 1995 - 1997 | Arzt im Praktikum (AiP) an der Psychiatrischen Klinik der LMU (Direktor: Prof. Dr. H.-J. Möller)  |
| 1996 - 1999 | Psychotherapeutische Weiterbildung mit dem Schwerpunkt kognitive Verhaltenstherapie, tiefenpsychologische Psychotherapie als Zweitverfahren   |
| 1997        | Promotion mit dem Thema: „Verlaufsuntersuchung der sakkadischen Augenbewegungen bei schizophrenen Patienten vor und unter Behandlung mit Neuroleptika“, Psychiatrische Klinik der LMU (Magna cum Laude) |
| 1997        | Vollapprobation als Arzt  |

1997 - 2002	wissenschaftlicher Mitarbeiter an der Psychiatrischen Klinik der LMU
1998 - 2010	Leiter der Arbeitsgruppe Klinische Psychopharmakologie
1999	ECNP Fellowship Award 1999
2000 - 2001	wissenschaftlicher Mitarbeiter an der Neurologischen Klinik (Friedrich-Baur-Institut) der LMU (Direktor: Prof. Dr. Dr. Th. Brandt)
2002 - 2010	Oberarzt an der Psychiatrischen Klinik der LMU - Oberarzt der Akutaufnahme
2003 - 2010	Oberarzt der Poliklinik und Institutsambulanz
2004 - 2010	Oberarzt der Tagesklinik
2005 - 2010	Oberarzt der medizinischen Dokumentation/Archiv
2005 - 2010	Leitender Oberarzt an der Psychiatrischen Klinik der LMU - Oberärztliche Koordination in Zusammenarbeit mit der Verwaltung des Klinikums und externen Wirtschaftsprüfungsgesellschaften (Lofert & Lofert, Ernst & Young) - Verantwortlicher Oberarzt für den Sachmittel- und Investitionshaushalt der Klinik
2006	Anerkennung: Facharzt für Psychiatrie und Psychotherapie
2006 - 2010	Verantwortlicher Oberarzt für die Bereiche Physiotherapie und Ergotherapie Verantwortlicher Oberarzt für den Sozialdienst
2007	Habilitation mit dem Thema: Kognitive Störungen schizophrener Patienten in der akuten Krankheitsepisode: Zusammenhänge mit der Psychopathologie und medikamentöse Beeinflussbarkeit
2008 - 2010	Mitglied der Kommission zur Wirtschaftlichkeits- und Qualitätsprüfung Psychiatrischer Institutsambulanzen
2009 - 2011	Berufsbegleitender Studiengang für Krankenhausmanagement (Deutsche Eliteakademie)
seit 2009	Supervisor am IFT [staatlich anerkanntes Ausbildungsinstitut für Ausbildung zum Psychologischen Psychotherapeuten/-in (VT)]
seit 2010	Supervisor für Verhaltenstherapie (Deutsche Ärztliche Gesellschaft für Verhaltenstherapie)
2010 - 2016	Chefarzt der Abteilung Psychiatrie und Psychosomatik am Vinzenz von Paul Hospital Rottweil
2011	Fusion der Abteilung Psychiatrie und Psychosomatik und der Abteilung Psychiatrie und Psychotherapie zum Zentrum für

	Allgemeinpsychiatrie, Psychotherapie und Psychosomatik am Vinzenz von Paul Hospital
seit 2011	Supervisor an der Tübinger Akademie für Verhaltenstherapie (TAVT)
2012	Vorzeitige Ernennung zum außerplanmäßigen Professor an der LMU aufgrund außergewöhnlicher Leistungen
seit 2012	Supervisor an der Ausbildungsakademie der Deutschen Gesellschaft für Verhaltenstherapie (dgvTA)
2013 – 11/2016	Ärztlicher Leiter des Vinzenz von Paul Hospitals
12/2016 – 6/2017	Chefarzt am Klinikum Nordschwarzwald (zfp Calw)
7/2017 – 6/2020	Ärztlicher Direktor und Chefarzt am Sächsischen Krankenhaus Rodewisch
seit 7/2020	Ärztlicher Direktor und Geschäftsführer am Marion von Tessin Memory-Zentrum gGmbH

### **Mitgliedschaften:**

- European Psychiatric Association (EPA)  
Gewähltes Mitglied der Sektion "Psychopharmacology" der AEP (Funktion:  
Schatzmeister bis 2013)
- European College of Neuropsychopharmacology (ECNP)
- World Psychiatric Association (WPA)  
Gewähltes Mitglied der Sektion "Immunology and Psychiatry" der WPA
- Arbeitsgemeinschaft für Neuropsychopharmakologie (AGNP)  
Gewähltes Mitglied der Arbeitsgruppe „TDM“ (Therapeutisches Drugmonitoring)
- Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN)
- Deutsche Gesellschaft für Biologische Psychiatrie (DGBP)
- Deutsche ärztliche Gesellschaft für Verhaltenstherapie (DGVT)

**Publikationsverzeichnis**  
**Prof. Dr. M. Riedel**

- I. Originalarbeiten**
- II. Fallberichte**
- III. Übersichtsartikel**
- IV. Buchkapitel**

**I Originalarbeiten**

1. Müller N, Dobmeier P, Empl M, **Riedel M**, Schwarz MJ, Ackenheil M: Soluble IL-6 Receptors in the serum and cerebrospinal fluid of paranoid schizophrenic patients. In: European Psychiatry, 1997, 12, 294 - 299  
Impact-Faktor: 0.497
2. Müller N, Empl M, **Riedel M**, Schwarz MJ, Ackenheil M: Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. In: Eur Arch Psychiatry Clin Neurosci, 1997, 247 (6), 308 - 313  
Impact-Faktor: 1.409
3. Straube A, Mennicken JB, **Riedel M**, Eggert T, Müller N: Saccades in Gilles de la Tourette's syndrom. In: Mov Disord, 1997, 12 (4), 536 – 546  
Impact-Faktor: 2.3
4. Müller N, Schlesinger BC, Hadjamu M, **Riedel M**, Schwarz MJ, Primbs J, Ackenheil M, Wank R, Gruber R: Increased frequency of Cytotoxic gamma/delta cells in unmedicated schizophrenic patients: Relation to impairment of the Blood-Brain-Barrier and HLA allele DPA 02011. In: Schizophr Res, 1998, 32, 69 – 71  
Impact-Faktor: 2.496
5. Schwarz MJ, Ackenheil M, **Riedel M**, Müller N: Blood-CSF-Barrier impairment as indicator for an immune process in schizophrenia. Neurosci Letters, 1998, 253, 201 - 203  
Impact-Faktor: 1.934
6. Schwarz MJ, **Riedel M**, Gruber R, Müller N, Ackenheil M: Autoantibodies against 60-kDa heat shock protein in schizophrenia. In: Eur Arch Psychiatry Clin Neurosci, 1998, 248, 282 - 288  
Impact-Faktor: 0.959
7. Empl M, Sostak P, Breckner M, **Riedel M**, Müller N, Gruber G, Forderreuther S, Straube A: T-cell subsets and expression of integrins in peripheral blood of patients with migraine. In: Cephalalgia, 1999, 19 (8), 713 – 717  
Impact-Faktor: 2.759

8. Schwarz MJ, **Riedel M**, Gruber R, Ackenheil M, Müller N: Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. In: *Am J Psychiatry*, 1999, 156 (7), 1103 - 1104  
Impact-Faktor: 6.341
9. Müller N, **Riedel M**, Eggert T, Straube A: Internally and externally guided voluntary saccades in unmedicated and medicated schizophrenic patients. Part II. Saccadic latency, gain and fixation suppression errors. *Eur Arch Psychiatry Clin Neurosci*, 1999, 149 (1), 7 - 14  
Impact-Faktor: 1.048
10. Straube A, **Riedel M**, Eggert T, Müller N: Internally and externally guided voluntary saccades in unmedicated and medicated schizophrenic patients. Part I. Saccadic velocity. In: *Eur Arch Psychiatry Clin Neurosci*, 1999, 249 (1), 1 - 6  
Impact-Faktor: 1.048
11. Müller N, Hadjuma M, **Riedel M**, Schwarz MJ, Ackenheil M, Gruber R: Increase in Expression of Adhesion-Molecule Receptor on T Helper Cells During Antipsychotic Treatment and Relationship to Blood-Brain-Barrier Permeability in Schizophrenia. *Am J Psychiatry*, 1999, 156, 634 - 636  
Impact-Faktor: 6.341
12. Frodl T, Juckel G, Gallinat J, Bottlender R, **Riedel M**, Preuss U, Möller HJ, Hegerl U: Dipole localization of P300 and normal aging. In: *Brain Topography*, 2000, 13 (1), 3 - 9  
Impact-Faktor: 1.596
13. Tigges P, Mergl R, Frodl T, Meisenzahl EM, Gallinat J, Schröter A, **Riedel M**, Müller N, Möller HJ, Hegerl U: Digitized analysis of abnormal hand-motor performance in schizophrenic patients. In: *Schizophr. Res*, 2000, 45 (1-2), 133 - 143  
Impact-Faktor: 3.506
14. Zill P, Baghai TC, Zwanzger P, Schüle C, Minov C, **Riedel M**, Neumeier K, Rupprecht R, Bondy B: Evidence for an association between a G-protein beta3-gene variant with depression and response to antidepressant treatment. In: *Neuroreport*, 2000, 11 (9), 1893 - 1897  
Impact-Faktor: 2.696
15. Müller N, **Riedel M**, Straube A, Günther W, Wilske B: Increased antistreptococcal antibodies in patients with Tourette's syndrome. In: *Psychiatry Res*, 2000, 94 (1), 43 - 49  
Impact-Faktor: 1.557
16. Müller N, **Riedel M**, Forderreuther S, Blendinger C, Abele-Horn M: Tourette's Syndrome and mycoplasma pneumoniae infection. In: *Am J Psychiatry*, 2000, 157 (3), 481 - 482  
Impact-Faktor: 6.577
17. Schwarz MJ, **Riedel M**, Ackenheil M, Müller N: Decreased Levels of Soluble Intracellular Adhesion Molecule - 1 (sICAM) in unmedicated and medicated schizophrenic patients. In: *Biol Psychiatry*, 2000, 47, 29 - 33  
Impact-Faktor: 4.269

18. Gallinat J, **Riedel M**, Juckel G, Sokullo S, Frodl T, Moukhtieva R, Mavrogiorgou P, Nissle S, Müller N, Danker-Hopfe H, Hegerl U: P300 and symptom improvement in schizophrenia. In: *Psychopharmacology*, 2001, 158 (1), 55 – 65  
Impact-Faktor: 3.145
19. Müller N, Kroll B, Schwarz MJ, **Riedel M**, Straube A, Lutticken R, Reinert RR, Reineke T, Kuhnemund O: Increased titers of antibodies against streptococcal M12 and M19 proteins in patients with Tourette`s syndrome. In: *Psychiatry Res*; 2001, 101 (2), 187 - 193  
Impact-Faktor: 1.775
20. Schwarz MJ, Müller N, **Riedel M**, Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. In: *Med Hypotheses*, 2001, 56 (4), 483 - 486  
Impact-Faktor: 0.745
21. Müller N, **Riedel M**, Scheppach C, Brandstätter B, Sokullo S, Krampe K, Ulmschneider M, Engel RR, Möller HJ, Schwarz MJ: Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. In: *Am J Psychiatry*, 2002, 159 (6), 1029 – 1034  
Impact-Faktor: 6.458
22. **Riedel M**, Kronig H, Schwarz MJ, Engel RR, Kühn KU, Sikorski C, Sokullo S, Ackenheil M, Möller HJ, Müller N: No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia: In: *Eur Arch Psychiatry Clin Neurosci*, 2002, 252 (5), 232 – 234  
Impact-Faktor: 2.076
23. **Riedel M**, Kronig H, Schwarz MJ, Engel RR, Sikorski C, Kühn KU, Behrens S, Möller HJ, Ackenheil M, Müller N: Investigation of the ICAM-1 G241A and A469G gene polymorphism in schizophrenia. In: *Mol-Psychiatry*, 2003, 8(3), 257-258  
Impact-Faktor: 5.539
24. Pogarell O, Hamann C Popperl G, Juckel G, Chouker M, Zaudig M, **Riedel M**, Möller HJ, Hegerl U, Tatsch K: Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. In: *Biol Psychiatry*, 2003, 54 (12), 1406 – 1413  
Impact-Faktor: 6.039
25. Juckel G, Gallinat J, **Riedel M**, Sokullo S, Schulz C, Möller HJ, Müller N, Hegerl U: Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity. In: *Schizophr Res*, 2003, 64 (2-3), 115 - 124  
Impact-Faktor: 4.072
26. Empl M, Sostak P, **Riedel M**, Schwarz MJ, Müller N, Forderreuther S, Straube A: Decreased sTNF-Ri in migraine patients? In: *Cephalalgia*, 2003, 23 (1), 55 – 58  
Impact-Faktor: 2.985
27. Pogarell O, Tatsch K, Juckel G, Hamann C, Mulert C, Popperl G, Folkerts M, Chouker M, **Riedel M**, Zaudig M, Möller HJ, Hegerl U: Serotonin and Dopamine Transporter Availabilities Correlate with the Loudness Dependence of Auditory Evoked Potentials in

- Patients with Obsessive-Compulsive Disorder. In: Neuropsychopharmacology, 2004, 29 (10), 1910 - 1917  
Impact-Faktor: 4.941
28. Möller HJ, **Riedel M**, Müller N, Fischer W, Kohnen R: Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. In: Pharmacopsychiatry, 2004, 37 (6), 270 – 278  
Impact-Faktor: 2.089
  29. **Riedel M**, Strassnig M, Müller N, Zwack P, Möller HJ: How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials? In: Eur Arch Psychiatry Clin Neurosci, 2005, 255 (2), 143 – 148  
Impact-Faktor: 2.264
  30. Müller N, **Riedel M**, Blendinger C, Oberle K, Jacobs E, Abele Horn M: Mycoplasma pneumoniae infection and Tourette`s syndrom. In: Psychiatry Research, 2004, 129 (2), 119 - 125  
Impact-Faktor: 1.989
  31. Kühn KU, Quednow BB, Landen H, **Riedel M**, Thiel M: Lebensqualität und Therapieerfolg in der ambulanten Schizophrenie-Therapie mit Flupentixol: Eine Anwendungsbeobachtung. In: Fortschritte der Neurologie Psychiatrie, 2004, 72, 397 - 403  
Impact-Faktor: 0.752
  32. Naber D, **Riedel M**, Klimke A, Vorbach EU, Lambert M, Kühn KU, Bender S, Bandelow B, Lemmer W, Moritz S, Dittmann RW: randomized double-blind comparison of olanzapine versus clozapine on subjective well-being and clinical outcome in patients with schizophrenia. In: Acta Psychiatr Scand, 2005, 111 (2), 106 – 115  
Impact-Faktor: 2.968
  33. **Riedel M**, Müller N, Strassnig M, Spellmann I, Engel RR, Musil R, Dehning S, Douhet A, Schwarz MJ, Möller HJ: Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. In: Eur Arch Psychiatry Clin Neurosci, 2005, 255, 432 – 437  
Impact-Faktor: 2.264
  34. Krönig H, **Riedel M**, Schwarz MJ, Strassnig M, Möller HJ, Ackenheil M, Müller N: ICAM G241A Polymorphism and Soluble ICAM-1 Serum Levels; Evidence for a Active Immune Process in Schizophrenia. In: Neuroimmunomodulation, 2005, 12, 54 - 59  
Impact-Faktor: 1.547
  35. Müller N, **Riedel M**, Schwarz MJ, Engel RR: Clinical effects of COX-2 inhibitors on cognition in schizophrenia. In: Eur Arch Psychiatry Clin Neurosci, 2005, 255 (2), 149 - 151  
Impact-Faktor: 2.264
  36. **Riedel M**, Schwarz MJ, Strassnig M, Spellmann I, Müller-Ahrends A, Weber K, Zach J, Müller N, Möller HJ: Risperidone plasma levels, clinical response and side-effects. In: Eur Arch Psychiatry Clin neurosci, 2005, 255, 261 – 268



Impact-Faktor: 2.264

37. Schwarz MJ, Krönig H, **Riedel M**, Dehning S, Douhet A, Spellmann I, Ackenheil M, Möller HJ, Müller N: IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. In: Eur Arch Psychiatry Clin Neurosci, 2006, 256, 72 - 76  
Impact-Faktor: 2.264
38. Kühn KU, Quednow BB, **Riedel M**, Krampe K, Maier W: Sicherheit und Effektivität von Citalopram in der Behandlung depressiver Erkrankungen. In: Psychopharmakotherapie, 2005, 3 (12), 83 - 90  
Impact-Faktor: 0.262
39. Pogarell O, Poepperl G, Mulert C, Hamann C, Sadowski N, **Riedel M**, Möller HJ, Hegerl U, Tatsch K: SERT and DAT availabilities under Citalopram treatment in obsessive-compulsive disorder (OCD). In: Eur Neuropsychopharmacol, 2005, 15 (5), 521 – 524  
Impact-Faktor: 3.510
40. Bender S, Dittmann-Balcar A, Schall U, Wolstein J, Klimke A, **Riedel M**, Vorbach EU, Kühn KU, Lambert M, Dittmann RW, Naber D: Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine versus clozapine. In: Int J Neuropsychopharmacol, 2005, 21, 1 – 11  
Impact-Faktor: 3.981
41. Müller N, Schwarz MJ, Dehning S, Douhet A, Cerovecki A, Goldstein-Müller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, **Riedel M**. The Cyclo-oxygenase-2 Inhibitor Celecoxib has therapeutic effects in Major Depression: Results of a double-blind, randomized, placebo-controlled, add-on Pilot Study of Rboxetine. In: Molecular Psychiatry, 2006;11 (7); 680-4  
Impact-Faktor: 11.804
42. **Riedel M**, Spellmann I, Schwarz MJ, Strassnig M, Sikorski C, Möller HJ, Müller N: Decreased T cellular immune response in schizophrenic patients. In: Jour of Psych Research, 2007; 41 (1-2):3-7  
Impact-Faktor: 3.71
43. Jäger M, **Riedel M**, Möller HJ: Die akuten vorübergehenden psychotischen Störungen (ICD-10: F 23) – Empirische Befunde und Implikationen für die Therapie. In: Nervenarzt, 2007;78:749-752  
Impact-Faktor: 0.601
44. Dittmann S, Seemüller F, Schwarz MJ, Zach J, fast K, Grunze H, Born C, Engel RR, Möller HJ, **Riedel M**, Severus WE: The impact of Homocysteine Levels on Cognition in Euthymic Bipolar patients: A Cross-Sectional Study. In: Journal of Clinic Psych, 2007 Jun; 69(6): 899-906  
Impact-Faktor: 5.060
45. Seemüller F, Volkmer E, Vogel T, Hummel T, Krauseneck T, **Riedel M**, Padberg F: Quetiapine as treatment for delirium during weaning from ventilation – a case report. J Clin psychopharmacol, 2007 Oct, 27(5); 526-8

46. **Riedel M**, Müller N, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Möller HJ: Efficacy of Olanzapine versus Quetiapine with regard to Cognitive Dysfunction in Patients with an acute Episode of Schizophrenia. In: *Eur Arch Psychiatry Clin Neurosci*, 2007, Oct; 257 (7): 402-12  
Impact-Faktor: 2.809
47. **Riedel M**, Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Müller N, Möller HJ: Effects of Risperidone and Quetiapine on Cognition in Patients with Schizophrenia and predominantly negative Symptoms. In: *Eur Arch Psychiatry Clin Neurosci*, 2007, 257(6):360-370  
Impact-Faktor: 2.809
48. Meisenzahl EM, Scheuerecker J, Zipse M, Ufer S, Wiesmann M, Frodl T, Koutsouleris N, Zetzsche T, Schmitt G, **Riedel M**, Spellmann I, Dehning S, Linn J, Bruckmann H, Möller HJ: Effects of treatment with the atypical neuroleptic quetiapine on working memory function: a functional MRI follow-up investigation. In: *Eur Arch Psychiatry Clin Neurosci*. 2006; 256 (8): 522 – 531  
Impact-Faktor: 3.042
49. Jäger M, **Riedel M**, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gabel W, Huff W, Heuser I, Kuhn KU, Lemke MR, Rütther E, Buchkremer G, Gastpar M, Bottlender R, Strauss A, Möller HJ: Psychopathological characteristics and treatment response of first episode compared with multiple episode schizophrenic disorders. In: *Eur Arch Psychiatry Clin Neurosci*. 2007 Feb; 257 (1): 47-53  
Impact-Faktor: 2.809
50. de la Fontaine L, Schwarz MJ, **Riedel M**, Dehning S, Douhet A, Spellmann I, Kleindienst N, Zill P, Plischke H, Gruber R, Müller N: Investigating disease susceptibility and the negative correlation of schizophrenia and rheumatoid arthritis focusing on MIF and CD14 gene polymorphisms. *Psychiatry Res* 2006; 144 (1) : 39-47  
Impact-Faktor: 2.31
51. Maino K, Gruber R, **Riedel M**, Seitz N, Schwarz MJ, Müller N: T- and B-lymphocytes in patients with schizophrenia in acute psychotic episode and the course of the treatment. *Psychiatry Research* 2007 Aug 30; 152 (2-3): 173-80.  
Impact-Faktor: 2.298
52. Sailer U, Eggert T, Strassnig M, **Riedel M**, Straube A.: Predictive eye and hand movements are differentially affected by schizophrenia. *Eur Arch Psychiatry Clin Neurosci*. 2007 Oct; 257 (7): 413-22  
Impact-Faktor: 2.809
53. Jäger M, **Riedel M**, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Kühn KU, Lemke MR, Rütther E, Buchkremer G, Gastpar M, Bottlender R, Strauss A, Möller HJ: Prediction of symptom remission in schizophrenia during inpatient treatment. *World J Biol Psychiatry*. 2007 Sep 12;;1-9  
Impact-Faktor: 1.691
54. Seemüller F, **Riedel M**, Wickelmaier F, Adli M, Mundt C, Marneros A, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Jäger M, Möller HJ, Henkel V: Atypical symptoms in

- hospitalised patients with major depressive episode: frequency, clinical characteristics and internal validity. *J Affect Disord.* 2008; Jun; 108 (3): 271-8  
Impact-Faktor: 3.271
55. Musil R, Spellmann I, **Riedel M**, Dehning S, Douhet A, Maino K, Zill P, Müller N, Möller HJ, Bondy B: SNAP-25 gene polymorphism and weight gain in schizophrenic patients. *J Psychiatr Res.* 2008 Oct; 42 (12): 963-70  
Impact-Faktor: 4.679
  56. Opgen-Rhein M, Opgen-Rhein R, **Riedel M**, Müller N. Kardiale Nebenwirkungen bei Therapie mit Ziprasidon und Olanzapin ein naturalistischer Vergleich. *Psychopharmakotherapie* 2008 Mar; 2:61-66
  57. Jäger M, **Riedel M**, Schmauss M, Pfeiffer H, Laux G, Naber D, Gaebel W, Huff W, Schmidt LG, Heuser I, Buchkremer G, Kühn KU, Rüter E, Hoff P, Gastpar M, Bottlender R, Strauß A, Möller HJ: Depression during an acute episode of schizophrenia or schizophreniform disorder and its impact of treatment response. *Psychiatry Res.* 2008 Apr 15; 158 (3): 297-305  
Impact-Faktor: 2.666
  58. Dittmann S, Seemüller F, Grunze HC, Schwarz MJ, Zach J, Fast K, Born C, Dargel S, Engel RR, Bernhard B, Möller HJ, **Riedel M**, Severus WE: The Impact of Homocysteine Levels on Cognition in Euthymic Bipolar Patients: A Cross-Sectional Study. *J Clin Psychiatry.* 2008 Jun; 69 (6): 899-906  
Impact-Faktor: 5.053
  59. Dittmann S, Henning-Fast K, Gerber S, Seemüller F, **Riedel M**, Severus WE, Langosch J, Engel RR, Möller HJ, Grunze H; Cognitive functioning in euthymic bipolar I and bipolar II patients, *Bipolar Disorders* 2008 (10); 877-887  
Impact-Faktor: 3.959
  60. Möller HJ, **Riedel M**, Jäger M, Wickelmaier F, Maier W, Kühn KU, Buchkremer G, Heuser I, Klosterkötter J, Gastpar M, Braus DF, Schlösser R, Schneider F, Ohmann C, Riesbeck M, Gaebel W: Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. *Int J Neuropsychopharmacol.* 2008 Nov; 11 (7): 985-97  
Impact-Faktor: 4.378
  61. Werner NS, Meindl T, Engel RR, Rosner R, **Riedel M**, Reiser M, Fast K: Hippocampal function during associative learning in patients with posttraumatic stress disorder. *J Psychiatr Res.* 2009 Jan; 43 (3): 309-18  
Impact-Faktor: 3,723
  62. Spellmann I, Müller N, Musil R, Zill P, Douhet A, Dehning S, Cerovecki A, Bondy B, Möller HJ, **Riedel M**: Associations of SNAP-25 polymorphism with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trail of treatment with atypical antipsychotics. In: *Eur Arch Psychiatry Clin Neurosci.* 2008 Vol. 258 Nr. 6 S. 335-344  
Impact-Faktor: 2.852

63. Dittmann S, Fast K, Dederra K, Seemüller F, Möller HJ, **Riedel M**, Severus E: Kognitive Funktionsfähigkeit bei bipolaren Erkrankungen. In: Nervenheilkunde 2008 Nr. 3, S. 155-164  
Impact-Faktor: 0.373
64. Seemüller F, **Riedel M**, Obermeier M, Bauer M, Adli M, Mundt C, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Jäger M, Henkel V, Möller HJ: The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of inpatients with major depressive episode. In: Int. J. Neuropsychopharmacol. 2009 Mar; 12 (2): 181-9  
Impact-Faktor: 4.874
65. Dehning S, **Riedel M**, Müller N: Father-to-Son Transmission of 6;17 Translocation in Tourette's Syndrome. In: Am J Psychiatry 2008 Aug; 165 (8): 1051-2  
Impact-Faktor: 10.545
66. Jäger M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüter E, Buchkremer G, Gastpar M, **Riedel M**, Bottlender R, Strauß A, Möller HJ: Standardized Remission Criteria in Schizophrenia: Descriptive Validity and Comparability with previously Used Outcome Measures. In: Pharmacopsychiatry 2008 Sep; 41 (5): 190-195  
Impact-Faktor: 2.402
67. **Riedel M**, Eich FX, Möller HJ: A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. In: European Psychiatry 2009, Vo. 24, Nr. 3, S 149-153  
Impact-Faktor: 3.080
68. Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, **Riedel M**: Does early improvement triggered by antidepressants predict response/remission? – Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord. 115 (2009) 439-449  
Impact-Faktor: 3.763
69. Egli S, **Riedel M**, Möller HJ, Strauß A, Läge D: Creating a map of psychiatric patients based on psychopathological symptom profiles. Eur. Arch Psychiatry Clin Neurosci 2009 Apr; 259 (3):164-71  
Impact-Faktor: 2.747
70. Seemüller F, Severus E, Möller HJ, **Riedel M**: Antidepressants and suicidality in younger adults – is bipolar illness the missing link? In: Acta Psychiatr Scand. 2009 Feb; 119 (2): 166-167  
Impact-Faktor: 3.733
71. Möller HJ, Seemüller F, **Riedel M**: Time course of response and remission during antidepressant treatment. In: Medicographia, Vol. 31, No. 2, 2009, S.118-125
72. **Riedel M**, Seemüller F, Wickelmaier F, Schennach-Wolff, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Häuser I, Zeiler J, Gaebel W, Jäger M, Möller HJ, Henkel

V: Häufigkeit, klinische Charakteristika und interne Validität von atypischen depressiven Symptomen bei stationären Patienten mit Major Depression. In: Nervenheilkunde 2009, Nr. 4, S. 1-7

Impact-Faktor: 0.373 (2008)

73. Thomas P, Alptekin K, Gheorghe M, Mauri M, Olivares JM, **Riedel M**. Management of patients presenting with acute psychotic episodes of schizophrenia. In: CNS Drugs 2009; 23 (3): 193-212  
Impact-Faktor: 3.879
74. Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser T, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, Möller HJ, **Riedel M**. Attitude towards adherence in patients with schizophrenia at discharge. J Psychiatr Res. 2009 Dec;43 (16):1294-301  
Impact-Faktor: 4.723
75. Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Degner D, Buchkremer G, Gastpar M, Möller HJ, **Riedel M**. Early improvement as a predictor of remission and response in schizophrenia: results from a naturalistic study. Eur Psychiatry. 2009 Dec; 24 (8):501-6  
Impact-Faktor: 3.080
76. Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, naber D, Schmidt LG, Gaebel W, Huff W, Heuser I, Maier W, Lemke MR, Rütther E, Buchkremer G, Gastpar M, Möller HJ, **Riedel M**. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorder. In: Schizophr. Res. 2009 Sep; 113 (2-3):210-7  
Impact-Faktor: 4.458
77. Werner N, Meindl T, Materne J, Engel RR, Huber D, **Riedel M**, Reiser M, Henning-Fast K. Functional MRI study of memory-related brain regions in patients with depressive disorder. In: J Affect Disord. 2009 Dec; 119 (1-3):124-31  
Impact-Faktor: 3.763
78. **Riedel M**, Schennach-Wolff R, Spellmann I, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, Matz J, Seemüller F, Obermeier M, Severus E, Engel RR, Müller N, Möller HJ: Effects of Aripiprazole on cognition in the treatment of patients with schizophrenia. In: Pharmacopsychiatry 2010 Mar; 43 (82): 50-7  
Impact-Faktor: 2.317
79. Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Schmauss m, Laux G, Pfeiffer H, Naber D, Schmidt L, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke M, Rütther E, Klingberg S, Gastpar M, Möller HJ, **Riedel M**: Outcome of suicidal patients with schizophrenia: results from a naturalistic study. In Acta Psychiatr Scand. 2010 May;121 (5): 359-70  
Impact-Faktor: 3.733
80. Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütther E, Buchkremer G, Gastpar M, Möller HJ, **Riedel M**: Response and remission of subjective

well-being in patients suffering from schizophrenia spectrum disorders. *Eur Psychiatry* Apr 2010 , epub ahead  
Impact-Faktor: 3.365

81. Obermeier M, Mayr A, Schennach-Wolff R, Seemüller F, Möller HJ, **Riedel M**: Should the PANSS be rescaled?, *Schiz. Bulletin* 2010 May;36 (3):455-60  
Impact-Faktor: 8.273
82. Seemüller F, Schennach-Wolff R, Obermeier M, Henkel V, Möller HJ, **Riedel M**: Does early improvement in major depression protect against treatment emergent suicidal ideation? *J Affect Disord* 2010 Jul; 124 (1-2):183-6  
Impact-Faktor: 3.74
83. Seemüller F, Möller HJ, Obermeier M, Adli M, Bauer M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, **Riedel M**: Do efficacy and effectiveness samples differ in antidepressant treatment outcome? *J Clin Psychiatry* 2010 Nov;43 (7):245-51  
Impact-Faktor: 5.023
84. Krause D, Matz J, Weidinger E, Wagner J, Wildenauer A, Obermeier M, **Riedel M**, Müller N. Association between intracellular infectious agents and Tourette's syndrome. *Eur Arch Psychiatry Clin Neurosci.* 2010 Jun; 260 (4):359-63  
Impact-Faktor: 3.637
85. Karch S, Thalmeier T, Lutz J, Cerovecki A, Opgen-Rhein M, Hock B, Leicht G, Hennig-Fast K, Meindl T, **Riedel M**, Mulert C, Pogarell O: Neural correlates (ERP/fMRI) of voluntary selection in adult ADHD patients. In: *Eur Arch Psychiatry Clin Neurosci.* 2010 Aug; 260 (5): 427-40  
Impact-Faktor: 3.637
86. Dehning S, Matz J, **Riedel M**, Kerle IA, Müller N: Symptom exacerbation in Tourette syndrome due to bacterial reinfection. *J Clin Psychiatry.* 2009 Nov; 70(11): 1606.  
Impact-Faktor: 5.023
87. Frommann I, Pukrop R, Brinkmeyer J, Bechdolf A, Ruhrmann S, Berning J, Decker P, **Riedel M**, Möller HJ, Wölwer W, Gaebel W, Klosterkötter J, Maier W, Wagner M: Neuropsychological Profiles in Different At-Risk States of Psychosis: Executive Control Impairment in the Early- and Additional Memory dysfunction in the Late-Prodromal State. *Schizophr Bull.* 2010 Jan 6. [Epub ahead of print]  
Impact-Faktor: 8.273
88. Seemüller F, **Riedel M**, Obermeier M, Mauer M, Adli M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Dichgans E, Bottlender R, Musil R, Möller HJ: Outcomes of 1014 naturalistically treated inpatients with major depressive episode. *Eur Neuropsychopharmacol.* 2010;20 (5): 346-55  
Impact-Faktor: 4.201
89. Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Kühn KU, Lemke MR, Rütger E, Klingberg S, Gastpar M, Möller HJ, **Riedel M**: Quality of life and subjective

- well-being in schizophrenia and schizophrenia spectrum disorders – valid predictors of symptomatic response and remission? *World J Biol Psychiatry* 2010 Aug; 11 (5):729-38  
Impact-Faktor: 2.048
90. Jäger M, **Riedel M**, Obermeier M, Schennach-Wolff R, Seemüller F, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Kühn KU, Lemke MR, Rütther E, Klingberg S, Gastpar M, Bottlender R, Möller HJ: Time course of antipsychotic treatment response in schizophrenia: Results from a naturalistic study in 280 patients. *Schizophr Res.* 2010 May; 118 (1-3):183-8  
Impact-Faktor: 4.374
  91. **Riedel M**, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Matz J, Opgen-Rhein M, Seemüller F, Obermeier M, Engel RR, Müller N, Möller HJ, Spellmann I: Neurocognition and its influencing factors in the treatment of schizophrenia – effects of aripiprazole, olanzapine, quetiapine and risperidone. *Hum Psychopharmacol* 2010 Mar;25 (2):116-25  
Impact-Faktor: 2.607
  92. Dehning S, Müller N, Matz J, Bender A, Kerle I, Benninghoff J, Musil R, Spellmann I, Bondy B, Möller HJ, **Riedel M**, Zill P: A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome. *Psychiatr Genet.* 2010 Feb; 20(1): 35-8  
Impact-Faktor: 2.061
  93. **Riedel M**, Moeller HJ, Obermeier M, Schennach-Wolff R, Bauer M, Adli M, kronmüller K, Nickel T, Brieger P, laux G, Bender W, heuser I, Zeiler J, Gaebel W, Seemüller F: Response and remission criteria in major depression – A validation of current practice. *J Psychiatr Res.* 2010 Nov; 44 (15):1063-8  
Impactfactor: 3.827
  94. Moeller HJ, Jäger M, **Riedel M**, Obermeier M, Strauss A, Bottlender R: The Munich 15-year follow-up study (MUFUSSAD) on first-hospitalized patients with schizophrenia or affective disorder; comparison of psychopathological and psychosocial course and outcome and prediction of chronicity. *Eur Arch Psychiatry Clin Neurosci.* 2010 Aug; 260 (5):367-84  
Impactfactor: 3.637
  95. Schennach-Wolff R, Seemüller FH, Mayr A, Maier W, Klingberg S, Heuser I, Klosterkötter J, Gastpar M, Häfner H, Sauer H, Schneider F, Gaebel W, Jäger M, Moeller HJ, **Riedel M**: An early improvement threshold to predict response and remission in first-episode schizophrenia. *Br. J Psychiatry.* 2010 Jun; 186(6); 460-6  
Impactfactor: 6.619
  96. Spellmann I, Rujescu D, Musil R, Mayr A, Giegling I, Genius J, Zill P, Dehning S, Opgen-Rhein M, Cerovecki A, Hartmann AM, Schäfer M, Bondy B, Müller N, Möller HJ, **Riedel M**. Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. *J Psychiatr Res.* 2011 Feb;45 (2): 234-41  
Impactfactor: 4.664
  97. Müller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Möller HJ, Klauss V, Schwarz MJ, **Riedel M**. Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of

- celecoxib augmentation of amisulpride treatment. *Schizophr Res.* 2010 Aug; 121 (1-3):118-24  
Impactfactor: 4.374
98. Krause D, Matz J, Weidinger E, Wagner J, Wildenauer A, Obermeier M, **Riedel M**, Müller N. The association of infectious agents and schizophrenia. *World J Biol Psychiatry.* 2010 Aug;11(5):739-43.  
Impactfactor: 2.048
99. Seemüller F, Möller HJ, Obermeier M, Adli M, Bauer M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, **Riedel M**. Do efficacy and effectiveness samples differ in antidepressant treatment outcome? an analysis of eligibility criteria in randomized controlled trials. *J Clin Psychiatry.* 2010 Nov; 71(11):1425-33  
Impactfactor: 5.023
100. Läge D, Egli S, **Riedel M**, Strauss A, Möller HJ. Combining the categorical and the dimensional perspective in a diagnostic map of psychotic disorders. *Eur Arch Psychiatry Clin Neurosci.* 2010 Jul 30. [Epub ahead of print] PubMed PMID:20676665.  
Impactfactor: 3.637
101. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Lemke M, Heuser I, Maier W, Huff W, Schmitt A, Sauer H, **Riedel M**, Klingberg S, Köpcke W, Ohmann C, Möller HJ; for the German Study Group on First-Episode Schizophrenia. Relapse prevention in first-episode schizophrenia-maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the german research network on schizophrenia. *J Clin Psychiatry.* 2010 Jun 29. [Epub ahead of print] PubMed PMID: 20673559.  
Impactfactor: 5.023
102. **Riedel M**, Spellmann I, Schennach-Wolff R, Obermeier M, Musil R. The RSM-scale: a pilot study on a new specific scale for self- and observer-rated quality of life in patients with schizophrenia. *Qual Life Res.* 2011 Mar;20(2):263-72.  
Impactfactor: 1.958
103. Schennach-Wolff R, Möller HJ, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, **Riedel M**. A Critical Analysis and Discussion of the Appropriateness of the Schizophrenia Consensus Remission Criteria in Clinical Pharmaceutical Trials. *Pharmacopsychiatry.* 2010 Nov; 43 (7): 245-5  
Impactfactor: 2.203
104. Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, **Riedel M**, Möller HJ. Relationship between Baseline Severity of Depression and Antidepressant Treatment Outcome. *Pharmacopsychiatry.* 2010 Oct 27. [Epub ahead of print]  
Impactfactor: 2.203
105. Schennach-Wolff R, Obermeier M, Seemüller F, Jäger M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, Möller HJ, **Riedel M**. Evaluating depressive



symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. *Acta Psychiatr Scand.* 2010 Oct 4. [Epub ahead of print]  
Impactfactor: 3.795

106. Schennach-Wolff R, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütger E, Klingberg S, Gastpar M, Engel RR, Möller HJ, **Riedel M**. Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in nanaturalistic study. *J Clin Psychopharmacol.* 2010 Dec;30(6):726-31  
Impactfactor: 4.908
107. **Riedel M**, Severus E, Schennach-Wolff R, Musil R, Spellmann I, Oppolzer B, Möller HJ, Köhler J, Seemüller F. Effectiveness of quetiapine in outpatients with schizophrenia assessed under "real-life" conditions: a german clinical-practice evaluation programme. *J Clin Psychopharmacol.* 2011 Feb;31(1):120-2.  
Impactfactor: 4.908
108. Ilankovic LM, Allen PP, Engel R, Kambeitz J, **Riedel M**, Müller N, Hennig-Fast K. Attentional modulation of external speech attribution in patients with hallucinations and delusions. *Neuropsychologia.* 2011 Jan 14. [Epub ahead of print]  
Impactfactor: 3.636
109. Schennach-Wolff R, Jäger M, Mayr A, Meyer S, Kühn KU, Klingberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Schlösser R, Schneider F, Gaebel W, Seemüller F, Möller HJ, **Riedel M**. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients - Is it all about early response? *Eur Neuropsychopharmacol.* 2011 Jan 19. [Epub ahead of print]  
Impactfactor: 4.046
110. **Riedel M**, Mayr A, Seemüller F, Maier W, Klingberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Sauer H, Schneider F, Gaebel W, Jäger M, Möller HJ, Schennach-Wolff R. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: Comparing treatment with risperidone and haloperidol. *World J Biol Psychiatry.* 2011 May 13. [Epub ahead of print]  
Impact-Faktor: 2.385
111. Seemüller F, **Riedel M**, Obermeier M, Schennach-Wolff R, Spellmann I, Meyer S, Bauer M, Adli M, Kronmüller K, Ising M, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Möller HJ. The validity of self-rated psychotic symptoms in depressed inpatients. *Eur Psychiatry.* 2011 Mar 8. [Epub ahead of print]  
Impact-Faktor: 2.766
112. Costa A, **Riedel M**, Müller U, Möller HJ, Ettinger U. Relationship between SLC6A3 genotype and striatal dopamine transporter availability: A meta-analysis of human SPECT studies. *Synapse.* 2011 Mar 14.[Epub ahead of print] PubMed PMID  
Impact-Faktor: 2.945
113. **Riedel M**, Seemüller F, Schennach-Wolff R, Musil R, Spellmann I, Oppolzer B, Möller HJ, Köhler J, Severus E. Wirksamkeit und Verträglichkeit von Quetiapin im klinischen

- Alltag. Analyse einer Anwendungsbeobachtung bei Patienten mit schizophrenen Störungen in Deutschland (CLINPEP). *Psychopharmakotherapie*. 2011 18; 2: 75-83  
Impact-Faktor: 0.385
114. **Riedel M**, Möller HJ, Obermeier M, Adli M, Bauer M, Kronmüller K, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Schennach-Wolff R, Henkel V, Seemüller F. Clinical predictors of response and remission in inpatients with depressive syndromes. *J Affect Disord*. 2011 2011 Sep;133(1-2):137-49  
Impact-Faktor: 3.517
115. Musil R, Schwarz MJ, **Riedel M**, Dehning S, Cerovecki A, Spellmann I, Arolt V, Müller N. Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression - No influence of celecoxib treatment. *J Affect Disord*. 2011 Jun 16. [Epub ahead of print]  
Impact-Faktor: 3.517
116. Obermeier M, Schennach-Wolff R, Meyer S, Moller HJ, **Riedel M**, Krause D, Seemuller F. Is the PANSS used correctly? A systematic review. *BMC Psychiatry*. 2011 Jul 18;11(1):113. [Epub ahead of print]  
Impact-Faktor: 2.552
117. **Riedel M**, Leucht S, Rütger E, Schmauß M, Möller HJ. Critical trial-related criteria in acute schizophrenia studies. *Eur Arch Psychiatry Clin Neurosci*. 2011 Jul 26. [Epub ahead of print]  
Impact-Faktor: 3.494
118. Schennach-Wolff R, Meyer S, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütger E, Klingberg S, Gastpar M, Möller HJ, **Riedel M**. Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder. *J Psychiatr Res*. 2011 Dec; 45(12):1639-47  
Impactfactor: 4.664
119. Krause D, Wagner J, Matz J, Weidinger E, Obermeier M, **Riedel M**, Gruber R, Schwarz M, Mueller N. Monocytic HLA DR antigens in schizophrenic patients. *Neurosci Res*. 2011 Sep 22. [Epub ahead of print]  
Impactfactor: 2.25
120. Bechdolf A, Müller H, Stützer H, Wagner M, Maier W, Lautenschlager M, Heinz A, de Millas W, Janssen B, Gaebel W, Michel TM, Schneider F, Lambert M, Naber D, Brüne M, Krüger-Özgürdal S, Wobrock T, **Riedel M**, Klosterkötter J; PREVENT study group. Rationale and baseline characteristics of PREVENT: a second-generation intervention trial in subjects at-risk (prodromal) of developing first-episode psychosis evaluating cognitive behavior therapy, aripiprazole, and placebo for the prevention of psychosis. *Schizophr Bull*. 2011 Sep;37 Suppl 2:S111-21.  
Impactfactor: 8.273
121. Finke K, Schwarzkopf W, Müller U, Frodl T, Müller HJ, Schneider WX, Engel RR, **Riedel M**, Möller HJ, Hennig-Fast K. Disentangling the adult attention-deficit hyperactivity disorder endophenotype: Parametric measurement of attention. *J Abnorm Psychol*. 2011 Aug 22. [Epub ahead of print]

Impact-Faktor: 9.42

122. Schennach R, **Riedel M**, Obermeier M, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, Seemüller F, Möller HJ. Remission and Recovery and their Predictors in Schizophrenia Spectrum Disorder: Results from a 1-Year Follow-Up Naturalistic Trial. *Psychiatr Q*. 2011 Oct 29. [Epub ahead of print]  
Impact-Faktor: 1.68
123. Läge D, Egli S, **Riedel M**, Möller HJ. Exploring the structure of psychopathological symptoms: a re-analysis of AMDP data by robust nonmetric multidimensional scaling. *Eur Arch Psychiatry Clin Neurosci*. 2011 Nov 8. [Epub ahead of print]  
Impact-Faktor: 3.494
124. Severus E, Lipkovich I, Seemüller F, Obermeier M, Grunze H, Bernhard B, Dittmann S, **Riedel M**, Möller HJ. The potential role of Marginal Structural Models (MSMs) in testing the effectiveness of antidepressants in the treatment of patients with major depression in everyday clinical practice. *World J Biol Psychiatry*. 2011 Nov 18. [Epub ahead of print]  
Impact-Faktor: 3.79
125. Schennach R, Obermeier M, Meyer S, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, Seemüller F, Möller HJ, **Riedel M**. Predictors of relapse in the year after hospital discharge among patients with schizophrenia. *Psychiatr Serv*. 2012 Jan 1;63(1):87-90.  
Impact-Faktor: 2.03
126. Krause DL, **Riedel M**, Müller N, Weidinger E, Schwarz MJ, Myint AM. Effects of antidepressants and cyclooxygenase-2 inhibitor on cytokines and kynurenines in stimulated in vitro blood culture from depressed patients. *Inflammopharmacology*. 2012 Jan 12. [Epub ahead of print]  
Impact-Faktor: 2.304
127. Völter C, **Riedel M**, Wöstmann N, Aichert DS, Lobo S, Costa A, Schmechtig A, Collier DA, Hartmann AM, Giegling I, Möller HJ, Quednow BB, Rujescu D, Kumari V, Ettinger U. Sensorimotor gating and D2 receptor signalling: evidence from a molecular genetic approach. *Int J Neuropsychopharmacol*. 2012 Jan 16:1-14. [Epub ahead of print]  
Impact-Faktor: 4.45
128. Krause DL, Wagner JK, Wildenauer A, Matz J, Weidinger E, **Riedel M**, Obermeier, Gruber R, Schwarz M, Müller N. Intracellular monocytic cytokine levels in schizophrenia show an alteration of IL-6. *Eur Arch Psychiatry Clin Neurosci*. 2012 Jan 21.  
Impact-Faktor: 3.20
129. Schennach R, Zill P, Obermeier M, Hauer D, Dehning S, Cerovecki A, Opgen-Rhein, M, Musil R, Spellmann I, Matz J, Krause D, Seemüller F, Müller N, Möller HJ, Bondy B, **Riedel M**. The CNR1 gene in depression and schizophrenia - Is there an association with early improvement and response. *Psychiatry Res*. 2012 Feb 25. [Epub ahead of print]

Impact-Faktor: 3.67

130. Spellmann I, **Riedel M**, Schennach R, Seemüller F, Obermeier M, Musil R, Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, Möller HJ. One-year functional outcomes of naturalistically treated patients with schizophrenia. *Psychiatry Res.* 2012 Mar 13. [Epub ahead of print]  
Impact-Faktor: 3.67
131. Schennach R, Musil R, Möller HJ, **Riedel M**. Functional Outcomes in Schizophrenia: Employment Status as a Metric of Treatment Outcome. *Curr Psychiatry Rep.* 2012 Apr 3.  
Impact-Faktor: 4.12
132. Matz J, Krause DL, Dehning S, **Riedel M**, Gruber R, Schwarz MJ, Müller N. Altered monocyte activation markers in Tourette's syndrome: a case control study. *BMC Psychiatry.* 2012 Apr 2;12(1):29  
Impact-Faktor: 3.73
133. Schennach R, Meyer S, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, Möller HJ, **Riedel M**. Insight in schizophrenia-course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder. *Eur Psychiatry.* 2012 Apr 27. [Epub ahead of print]  
Impact-Faktor: 3.285
134. Costa A, **Riedel M**, Pogarell O, Menzel-Zelnitschek F, Schwarz M, Reiser M, Möller HJ, Rubia K, Meindl T, Ettinger U. Methylphenidate Effects on Neural Activity During Response Inhibition in Healthy Humans. *Cereb Cortex.* 2012 May 10. [Epub ahead of print]  
Impact-Faktor: 6.828
135. Seemüller F, Lewitzka U, Bauer M, Meyer S, Musil R, Schennach R, **Riedel M**, Doucette S, Möller HJ. The Relationship of Akathisia with Treatment Emergent Suicidality among Patients with First-Episode Schizophrenia Treated with Haloperidol or Risperidone. *Pharmacopsychiatry.* 2012 May 21. [Epub ahead of print]  
Impact-Faktor: 2.109
136. Schennach R, Meyer S, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, Musil R, Möller HJ, **Riedel M**. Response trajectories in "real-world" naturalistically treated schizophrenia patients. *Schizophr Res.* 2012 Aug; 139(1-3):218-24.  
Impact-Faktor: 4.590
137. Severus E, Seemüller F, Berger M, Dittmann S, Obermeier M, Pfennig A, **Riedel M**, Frangou S, Moller HJ, Bauer M. Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression. *BMC Med.* 2012 Jul 2;10(1):67.

Impact-Faktor: 9.35

138. Schennach R, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütther E, Klingberg S, Gastpar M, **Riedel M**, Möller HJ. Evaluating Depressive Symptoms in Schizophrenia: A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. *Psychopathology*. 2012 Jul 12. [Epub ahead of print]  
Impact-Faktor: 1.615
139. Karch S, Segmiller F, Hantschk I, Cerovecki A, Opgen-Rhein M, Hock B, Dargel S, Leicht G, Hennig-Fast K, **Riedel M**, Pogarell O. Increased gamma oscillations during voluntary selection processes in adult patients with attention deficit/hyperactivity disorder. *J Psychiatr Res*. 2012 Aug 22. [Epub ahead of print]  
Impact-Faktor: 4.066
140. Seemüller F, Schennach R, Mayr A, Musil R, Jäger M, Maier W, Klingenberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Schlösser R, Schneider F, Ohmann C, Lewitzka U, Gaebel W, Möller HJ, **Riedel M**; for the German Study Group on First-Episode Schizophrenia. Akathisia and Suicidal Ideation in First-Episode Schizophrenia. *J Clin Psychopharmacol*. 2012 Oct;32(5):694-698.  
Impact-Faktor: 2.53
141. Schennach R, Riesbeck M, Mayr A, Seemüller F, Maier W, Klingberg S, Heuser I, Klosterkötter J, Gastpar M, Schmitt A, Sauer H, Schneider F, Jäger M, Wölwer W, Gaebel W, Möller HJ, **Riedel M**. Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients? *Acta Psychiatr Scand*. 2012 Sep 8. doi: 10.1111/acps.12006. [Epub ahead of print]  
Impact-Faktor: 4.857
142. Musil R, Zill P, Seemüller F, Bondy B, Obermeier M, Spellmann I, Bender W, Adli M, Heuser I, Zeiler J, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller HJ, **Riedel M**. No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. *Eur Arch Psychiatry Clin Neurosci*. 2012 Sep 11. [Epub ahead of print]  
Impact-Faktor: 3.20
143. Musil R, Zill P, Seemüller F, Bondy B, Meyer S, Spellmann I, Bender W, Adli M, Heuser I, Fisher R, Gaebel W, Maier W, Rietschel M, Rujescu D, Schennach R, Möller HJ, **Riedel M**. Genetics of emergent suicidality during antidepressive treatment-Data from a naturalistic study on a large sample of inpatients with a major depressive episode. *Eur Neuropsychopharmacol*. 2012 Oct 10  
Impact-Faktor: 4.595
144. Costa A, la Fougère C, Pogarell O, Möller HJ, **Riedel M**, Ettinger U. Impulsivity is related to striatal dopamine transporter availability in healthy males. *Psychiatry Res*. 2012 Nov 13.  
Impact-Faktor: 3.67

145. Liepelt R, Schneider JC, Aichert DS, Wöstmann N, Dehning S, Möller HJ, **Riedel M**, Dolk T, Ettinger U. Action blind: Disturbed self-other integration in schizophrenia. *Neuropsychologia*. 2012 Nov 7;50(14):3775-3780.  
Impact-Faktor: 3.477
146. Segmiller FM, Hermisson I, **Riedel M**, Seemüller F, Volkamer T, Laux G, Möller HJ, Brunnauer A. Driving Ability According to German Guidelines in Stabilized Bipolar I and II Outpatients Receiving Lithium or Lamotrigine. *J Clin Pharmacol*. 2013 Feb 20:1-7.  
Impact-Faktor: 2.55
147. Schennach R, **Riedel M**, Musil R, Möller HJ. Treatment Response in First-episode Schizophrenia. *Clin Psychopharmacol Neurosci*. 2012 Aug;10(2):78-87  
Impact-Faktor: 3.513
148. Soutschek A, Schwarzkopf W, Finke K, Hennig-Fast K, Müller HJ, **Riedel M**, Möller HJ, Sorg C, Schubert T. Interference control in adult ADHD: No evidence for interference control deficits if response speed is controlled by delta plots. *Acta Psychol (Amst)*. 2013 Mar 26;143(1):71-78.  
Impact-Faktor: 2.367
149. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, Heuser I, Maier W, Klosterkötter J, Falkai P, Schlösser R, Schmitt A, **Riedel M**, Klingberg S, Köpcke W, Ohmann C, Möller HJ. Rates and predictors of remission in first-episode schizophrenia within 1 year of antipsychotic maintenance treatment. Results of a randomized controlled trial within the German Research Network on Schizophrenia. *Schizophr Res*. 2013 May 1  
Impact-Faktor: 4.426
150. Chiang SS, **Riedel M**, Schwarz M, Mueller N. Is T-helper type 2 shift schizophrenia-specific? Primary results from a comparison of related psychiatric disorders and healthy controls. *Psychiatry Clin Neurosci*. 2013 May;67(4):228-36.  
Impact-Faktor: 2.025
151. Aichert DS, Derntl B, Wöstmann NM, Groß JK, Dehning S, Cerovecki A, Möller HJ, Habel U, **Riedel M**, Ettinger U. Intact emotion-cognition interaction in schizophrenia patients and first-degree relatives: Evidence from an emotional antisaccade task. *Brain Cogn*. 2013 Jun 24;82(3):329-336  
Impact-Faktor: 2.683
152. Cerovecki A, Musil R, Klimke A, Seemüller F, Haen E, Schennach R, Kühn KU, Volz HP, **Riedel M**. Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations. *CNS Drugs*. 2013 Jul 3.  
Impact-Faktor: 4.376
153. Lieb M, Palm U, Meyer S, Sarubin N, Mokhtari-Nejad R, **Riedel M**, Möller HJ, Seemüller F. [Risk Factors for Inpatient Suicide.]. *Psychiatr Prax*. 2013 Jul 18.

154. Dehning S, Gasperi S, Tesfaye M, Girma E, Meyer S, Krahl W, **Riedel M**, Möller HJ, Müller N, Siebeck M. Empathy without borders? Cross-cultural heart and mind-reading in first-year medical students. *Ethiop J Health Sci.* 2013 Jul;23(2):113-22  
Impact-Faktor: 1.08
155. Krause D, Weidinger E, Dippel C, **Riedel M**, Schwarz MJ, Müller N, Myint AM. Impact of different antipsychotics on cytokines and tryptophan metabolites in stimulated cultures from patients with schizophrenia. *Psychiatr Danub.* 2013 Dec;25(4):389-97.  
Impact-Faktor: 0.653
156. Zink M, Schirmbeck F, Rausch F, Eifler S, Elkin H, Solojenkina X, Englisch S, Wagner M, Maier W, Lautenschlager M, Heinz A, Gudlowski Y, Janssen B, Gaebel W, Michel TM, Schneider F, Lambert M, Naber D, Juckel G, Krueger-Oezguerdal S, Wobrock T, Hasan A, **Riedel M**, Müller H, Klosterkötter J, Bechdolf A. Obsessive-compulsive symptoms in at-risk mental states for psychosis: associations with clinical impairment and cognitive function. *Acta Psychiatr Scand.* 2014 Feb 26.  
Impact-Faktor: 5.605
157. Spellmann I, Rujescu D, Musil R, Giegling I, Genius J, Zill P, Dehning S, Cerovecki A, Seemüller F, Schennach R, Hartmann AM, Schäfer M, Müller N, Möller HJ, **Riedel M**. PLEKHA6 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. *Prog Neuropsychopharmacol Biol Psychiatry.* 2014 Feb 25. pii: S0278-5846(14)00035-9.  
Impact-Faktor: 3.689
158. Seemüller F, Meier S, Obermeier M, Musil R, Bauer M, Adli M, Kronmüller K, Holsboer F, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, **Riedel M**, Falkai P, Möller HJ. Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. *Eur Arch Psychiatry Clin Neurosci.* 2014 Mar 4.  
Impact-Faktor: 3.525
159. Mueller S, Costa A, Keeser D, Pogarell O, Berman A, Coates U, Reiser MF, **Riedel M**, Möller HJ, Ettinger U, Meindl T. The effects of methylphenidate on whole brain intrinsic functional connectivity. *Hum Brain Mapp.* 2014 May 23.  
Impact-Faktor: 5.969
160. Kasparbauer AM, Rujescu D, **Riedel M**, Pogarell O, Costa A, Meindl T, la Fougère C, Ettinger U. Methylphenidate Effects on Brain Activity as a Function of SLC6A3 Genotype and Striatal Dopamine Transporter Availability. *Neuropsychopharmacology.* 2014 Sep 15.  
Impact-Faktor: 7.048
161. Schennach R, **Riedel M**, Obermeier M, Spellmann I, Musil R, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rütger E, Klingberg S, Gastpar M, Möller HJ. What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. *Eur Arch Psychiatry Clin Neurosci.* 2014 Sep 27.  
Impact-Faktor: 3.525

162. Schennach R, **Riedel M**, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüter E, Klingberg S, Gastpar M, Möller HJ. What are depressive symptoms in acutely ill patients with schizophrenia spectrum disorder? *Eur Psychiatry*. 2015 Jan;30(1):43-50  
Impact-Faktor: 3.439
163. Voggt A, Berger M, Obermeier M, Löw A, Seemueller F, **Riedel M**, Moeller HJ, Zimmermann R, Kirchberg F, Von Schacky C, Severus E. Heart rate variability and Omega-3 Index in euthymic patients with bipolar disorders. *Eur Psychiatry*. 2015 Feb;30(2):228-32  
Impact-Faktor: 3.439
164. **Riedel M**, Schmitz M, Østergaard PK, Ferrannini L, Franco MA, Alfano V, Vansvik ED. Comparison of the effects of quetiapine extended-release and quetiapine immediate-release on cognitive performance, sedation and patient satisfaction in patients with schizophrenia: A randomised, double-blind, crossover study (eXtRa). *Schizophr Res*. 2015 Mar;162(1-3):162-8  
Impact-Faktor: 4.453
165. Schennach R, Möller HJ, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüter E, Klingberg S, Gastpar M, Musil R, Spellmann I, **Riedel M**. Challenging the understanding of significant improvement and outcome in schizophrenia - the concept of reliable and clinically significant change methods. *Int J Methods Psychiatr Res*. 2015 Jul 14.  
Impact-Faktor: 2.857
166. Samara MT, Leucht C, Leeflang MM, Anghelescu IG, Chung YC, Crespo-Facorro B, Elkis H, Hatta K, Giegling I, Kane JM, Kayo M, Lambert M, Lin CH, Möller HJ, Pelayo-Terán JM, **Riedel M**, Rujescu D, Schimmelmann BG, Serretti A, Correll CU, Leucht S. Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. *Am J Psychiatry*. 2015 Jul;172(7):617-29  
Impact-Faktor: 13.505
167. Gaebel W, Riesbeck M, Wölwer W, Klimke A, Eickhoff M, von Wilmsdorff M, de Millas W, Maier W, Ruhrmann S, Falkai P, Sauer H, Schmitt A, **Riedel M**, Klingberg S, Möller HJ. Predictors for symptom re-exacerbation after targeted stepwise drug discontinuation in first-episode schizophrenia: Results of the first-episode study within the German research network on schizophrenia. *Schizophr Res*. 2016 Jan;170(1):168-76.  
Impact-Faktor: 4.453
168. Rausch F, Eisenacher S, Elkin H, Englisch S, Kayser S, Striepens N, Lautenschlager M, Heinz A, Gudlowski Y, Janssen B, Gaebel W, Michel TM, Schneider F, Lambert M, Naber D, Juckel G, Krueger-Oezguerdal S, Wobrock T, Hasan A, **Riedel M**, Moritz S, Müller H, Klosterkötter J, Bechdolf A, Zink M, Wagner M. Evaluation of the 'Jumping to conclusions' bias in different subgroups of the at-risk mental state: from cognitive basic symptoms to UHR criteria. *Psychol Med*. 2016 Apr 20:1-11.  
Impact-Faktor: 5.491



169. Seemüller F, Obermeier M, Schennach R, Bauer M, Adli M, Brieger P, Laux G, **Riedel M**, Falkai P, Möller HJ. Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients. *BMC Psychiatry*. 2016 May 20;16:153.  
Impact-Faktor: 2.576
170. Kambeitz J, la Fougère C, Werner N, Pogarell O, **Riedel M**, Falkai P, Ettinger U. Nicotine-dopamine-transporter interactions during reward-based decision making. *Eur Neuropsychopharmacol*. 2016 Jun;26(6):938-47  
Impact-Faktor: 4.409
171. Spellmann I, Schennach R, Seemüller F, Meyer S, Musil R, Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Bauer M, Adli M, Zeiler J, Bender W, Kronmüller KT, Ising M, Brieger P, Maier W, Lemke MR, Rüter E, Klingberg S, Gastpar M, **Riedel M**, Möller HJ. Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies. *Eur Arch Psychiatry Clin Neurosci*. 2017 Jun;267(4):303-313
172. Cordes J, Bechdorf A, Engelke C, Kahl KG, Balijepalli C, Lösch C, Klosterkötter J, Wagner M, Maier W, Heinz A, de Millas W, Gaebel W, Winterer G, Janssen B, Schmidt-Kraepelin C, Schneider F, Lambert M, Juckel G, Wobrock T, **Riedel M**, Moebus S. Prevalence of metabolic syndrome in female and male patients at risk of psychosis. *Schizophr Res*. 2017 Mar;181:38-42
173. Müller H, de Millas W, Gaebel W, Herrlich J, Hasan A, Janssen B, Juckel G, Karow A, Kircher T, Kiszkenow-Bäker S, Klingberg S, Klosterkötter J, Krüger-Özgürdal S, Lambert M, Lautenschlager M, Maier W, Michel TM, Mehl S, Müller BW, Pützfeld V, Rausch F, **Riedel M**, Sartory G, Schneider F, Wagner M, Wiedemann G, Wittorf A, Wobrock T, Wölwer W, Zink M, Bechdorf A. Negative schemata about the self and others and paranoid ideation in at-risk states and those with persisting positive symptoms. *Early Interv Psychiatry*. 2017 May 19
174. Schennach R, Obermeier M, Seemüller F, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüter E, Klingberg S, Gastpar M, Spellmann I, Musil R, Möller HJ, **Riedel M**. Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder - When, Who, and How? *Pharmacopsychiatry*. 2017 Jul;50(4):136-144
175. Ettinger U, Aichert DS, Wöstmann N, Dehning S, **Riedel M**, Kumari V. Response inhibition and interference control: Effects of schizophrenia, genetic risk, and schizotypy. *J Neuropsychol*. 2017 May 8.
176. Spellmann I, **Riedel M**, Städtler J, Zill P, Obermeier M, Cerovecki A, Dehning S, Schennach R, Epple M, Opgen-Rhein M, Müller N, Bondy B, Möller HJ, Musil R. Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment. *Cogn Neuropsychiatry*. 2017 Jul;22(4):280-297.
177. Krause D, Myint AM, Schuett C, Musil R, Dehning S, Cerovecki A, **Riedel M**, Arolt V, Schwarz MJ, Müller N. High Kynurenine (a Tryptophan Metabolite) Predicts Remission in Patients with Major Depression to Add-on Treatment with Celecoxib.

Front Psychiatry. 2017 Feb 13;8:16.

178. Musil R, Seemüller F, Meyer S, Spellmann I, Adli M, Bauer M, Kronmüller KT, Brieger P, Laux G, Bender W, Heuser I, Fisher R, Gaebel W, Schennach R, Möller HJ, **Riedel M**. Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder. *Int J Methods Psychiatr Res*. 2018 Mar;27(1)
179. Spellmann I, Reinhard MA, Veverka D, Zill P, Obermeier M, Dehning S, Schennach R, Müller N, Möller HJ, **Riedel M**, Musil R. QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors. *Eur Arch Psychiatry Clin Neurosci*. 2018 Feb 10.
180. Schennach R, **Riedel M**, Spellmann I, Musil R, Obermeier M, Jäger M, Bottlender R, Schmauss M, Laux G, Möller HJ. Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study. *Pharmacopsychiatry*. 2019 Jul;52(4):180-185; Erratum Epub 2020 Feb 26
181. Schennach R, **Riedel M**, Obermeier M, Jäger M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, Maier W, Lemke MR, Rüter E, Klingberg S, Gastpar M, Seemüller F, Spellmann I, Musil R, Möller HJ. What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial. *Eur Arch Psychiatry Clin Neurosci*. 2020 Sep;270(6):661-671.
182. Kautzky A, Möller HJ, Dold M, Bartova L, Seemüller F, Laux G, **Riedel M**, Gaebel W, Kasper S. Combining machine learning algorithms for prediction of antidepressant treatment response. *Acta Psychiatr Scand*. 2021 Jan;143(1):36-49.
183. Seemüller F, Kolter M, Musil R, Schennach R, Adli M, Bauer M, Brieger P, Laux G, **Riedel M**, Falkai P, Möller HJ, Padberg F. Chronic vs non-chronic depression in psychiatric inpatient care - Data from a large naturalistic multicenter trial. *J Affect Disord*. 2022 Feb 15;299:73-84.

## II Übersichtsartikel

1. Müller N, **Riedel M**, Ackenheil M, Schwarz MJ: The role of immune function in schizophrenia: an overview. In: Eur Arch Psychiatry Clin Neurosci, 1999, 249 (4), 62 - 68  
Impact-Faktor: 1.048
2. Müller N, **Riedel M**, Ackenheil M, Schwarz MJ: Cellular humoral immune system in schizophrenia: a conceptual re-evaluation. In: World J Biol Psychiatry, 2000, 1 (4), 173 - 179  
Impact-Faktor: 2.800 (2005)
3. Müller N, **Riedel M**, Schaub A, Bondy B, Möller HJ, Ackenheil M: Use of typical and atypical antipsychotics in schizophrenia: pharmacological and clinical aspects: In: European Neuropharmacology, 2000, 10 (3), 131 - 132  
Impact-Faktor: 2.045
4. Müller N, **Riedel M**, Möller HJ: Amisulprid in der Therapie schizophrener Negativsymptomatik. In: Psychopharmakotherapie, 2000, 3, 111 - 116  
Impact-Faktor: 0.301
5. **Riedel M**, Müller N, Müller WE, Möller HJ: Nefazodon, ein duales serotineres Antidepressivum. In: Psychopharmakotherapie, 2000, 3, 117 - 124  
Impact-Faktor: 0.301
6. **Riedel M**, Müller N, Möller HJ: Atypische Neuroleptika. In: Akt Neurologie, 2000, 27, 340 - 348  
Impact-Faktor: 0.296
7. Müller N, **Riedel M**, Zawta P, Günther W, Straube A: Comorbidity of Tourette's syndrome and schizophrēnis – biological and physiological parallels. In: Prog Neuropsychopharmacol Biol Psychiatry, 2002, 26 (6-7), 1245 - 1252  
Impact-Faktor: 1.433
8. **Riedel M**, Strassnig M, Kühn KU, Müller N, Möller HJ: Aripiprazol: Führt ein neuer Wirkmechanismus zu einer neuen Qualität in der Schizophrenie-Therapie? Psychopharmakotherapie, 2003,10, 46 – 54  
Impact-Faktor: 0.684
9. Müller N, Strassnig M, Schwarz MJ, Ulmschneider M, **Riedel M**: COX-2 Inhibitors as adjunctive therapy in schizophrenia. In: Expert Opin Investig Drugs, 2004, 13 (8), 1033 - 1044  
Impact-Faktor: 3.588
10. Müller N, **Riedel M**, Schwarz MJ: Psychotropic Effects of COX-2 inhibitors – A Possible New Approach for the Treatment of Psychiatric Disorder. In: Pharmacopsychiatry, 2004, 37 (6), 266 - 269  
Impact-Faktor: 2.089
11. Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, Gruber R, **Riedel M**: COX-2 inhibition as a treatment approach in schizophrenia:

- Immunological considerations and clinical effects of Celecoxib add-on therapy. In: Eur Arch Psychiatry Clin Neurosci, 2004, 254, 14 - 22  
Impact-Faktor: 1.878
12. **Riedel M**, Strassnig M, Schwarz MJ, Müller N: COX-2 Inhibitors as Adjunctive Therapy in Schizophrenia: Rationale for Use and Evidence to Date. In: CNS Drugs, 2005, 19 (10), 805 - 819  
Impact-Faktor: 3.671
  13. Jäger M, **Riedel M**, Bottlender R, von Wilmsdorff M, Wölwer W, Gaebel W, Möller HJ, Maier W: Medikamentöse Akutbehandlung schizophrener Ersterkrankungen. In: Nervenheilkunde, 2006, 25, 32 - 36  
Impact-Faktor: 0.396
  14. **Riedel M**, Müller N, Möller HJ: Die Psychopharmakotherapie der Schizophrenie. In: Psychotherapie, 1999, 4 (1), 108 – 114
  15. **Riedel M**, Schaub A, Möller HJ: Pathogenetische Modellvorstellungen zur Schizophrenie. In: Psychotherapie, 1999, 4 (1), 48 – 55
  16. Müller N, **Riedel M**: Fehldiagnosen bei Zwangs- und Ticserkrankungen. Münchner Medizinische Wochenschrift, 1999, 141, 31 - 34
  17. Müller N, **Riedel M**, Gruber R, Ackenheil M, Schwarz MJ: The immune system and schizophrenia. An integrative view. In: Ann NY Acad. Sci, 2000, 917, 456 - 467
  18. Müller N, **Riedel M**, Möller HJ: Atypische Neuroleptika, Wirkstoffe gegen Wahn und Rückzug. In: Pharmazeutische Zeitung, 2000, 26 (145/43), 11 – 17
  19. **Riedel M**, Müller N, Möller HJ: Negativsymptome: Was tun? Atypische Neuroleptika im Einsatz bei schizophrener Negativsymptomatik. In: Ärztliche Praxis – Neurologie Psychiatrie, 2000, 4, 33 - 34
  20. Müller N, **Riedel M**: Weniger Nebenwirkungen! Therapie mit atypischen Neuroleptika. In: Pharm in unserer Zeit, 2002, 31 (6), 558 - 565
  21. Müller N, Ulmschneider M, Scheppach C, Schwarz MJ, Ackenheil M, Möller HJ, Gruber R, **Riedel M**: The role of Psychoneuroimmunology in schizophrenia. In: Psychiatria Danubia, 2003, 15, 131 - 132
  22. Lambert M, **Riedel M**, Möller HJ, Naber D: Das Antipsychotikum Aripiprazol – Wirksamkeit und Verträglichkeit. In: Die Psychiatrie, 2004, 1, 50 - 62
  23. **Riedel M**, Spellmann I, Severus E, Müller N, Möller HJ: Das Antipsychotikum Quetiapin in der Behandlung der Schizophrenie. In: Die Psychiatrie, 2005, 1, 55 - 69
  24. **Riedel M**, Spellmann I, Möller HJ: Das Antipsychotikum Ziprasidon in der Behandlung der Schizophrenie. In: Die Psychiatrie, 2005, 2/3, 179 - 194
  25. Jäger M, **Riedel M**, Möller HJ: Die Rolle des Hausarztes im Behandlungskonzept schizophrener Erkrankungen. In: MMW-Fortschritte der Medizin, 2006, Sonderheft 2

26. Seemüller F, **Riedel M**, Möller HJ, Henkel V: Atypische Depression – Unterschätzter Subtyp der depressiven Erkrankung. In: Der Neurologe & Psychiater, 2006, 7-8, 33-37
27. Seemüller F, Dittmann S, Bernhard B, **Riedel M**, Severus E: State of the Art – Bipolare Störungen. In: Pharma Fokus ZNS, 2006, September, 35-36
28. **Riedel M**, Spellmann I, Müller N, Möller HJ: Schizophrene Patienten in der Praxis – Was Sie als Hausarzt wissen müssen. In: MMW (Münchener Medizinische Wochenschrift), 2007, Sonderheft 2, 21. Mai 2007, 98-101
29. **Riedel M**, Müller N, Strassnig M, Spellmann I, Severus E, Möller HJ. Quetiapine in the treatment of schizophrenia. Neuropsychiatric Disease and Treatment. 2007, Volume 3 Issue 2.
30. **Riedel M**, Musil R, Spellmann I, Seemüller F, Möller HJ: Quetiapin XR – A New Retard Formulation in the Treatment of Schizophrenia. In: Eur. Psychiatric Review, 2009, Volume 1, Issue 2, S.70-75
31. **Riedel M**, Schennach-Wolf R, Musil R, Seemüller F, Spellmann I: Atypische Antipsychotika - Wie fällt der Wirksamkeitsvergleich aus? In: Der Neurologe & Psychiater, 2008, 12-18
32. Severus E, Seemüller F, Obermeier M, Schennach-Wolf R, Bernhard B, Dittmann S, Möller H.-J. **Riedel M**: Antidepressiva bei bipolarer Erkrankung. Eine evidenzbasierte Wirksamkeitsanalyse. In: Der Neurologe & Psychiater, 2008, 19-20
33. Müller N, Schennach R, **Riedel M**, Möller HJ: Duloxetine in the treatment of major psychiatric and neuropathic disorder. Expert Rev Neurother. 2008 Apr; 8 (4): 527-36. Review
34. Volz HP, Reischies F, **Riedel M**: Cognitive disorders in schizophrenic patients. Nervenarzt. 2010 Jan; 81(1): 39-54  
Impact-Faktor: 0.776 (2009)
35. Seemüller F, Dittmann S, Müller N, Opgen-Rhein M, **Riedel M**, Mahli GS: The Kraepelinian Chair: a defining seat? Acta neuropsychiatrica 2009 Oct; 21(5): 256-257  
Impact-Faktor: 0.944
36. Seemüller F, **Riedel M**, Dargel S, Djaja N, Schennach-Wolff R, Dittmann S, Moeller HJ, Severus E: Bipolar disorder: Spectrum of clinical pictures and differentiation from unipolar depression. Nervenarzt. 2010 May; 81 (5): 531-8  
Impact-Faktor: 0.776 (2009)
37. de Souza DS, **Riedel M**, Moeller HJ, Severus E: Bipolar disorder: update on current treatment options. MMW Fortschr Med. 2010 Mar 4; 152(9): 50-2
38. **Riedel M**, Musil R, Seemüller F, Spellmann I, Moeller HJ, Schennach-Wolff R: Safety evaluation of zotepine for treatment of schizophrenia. Expert Opin drug Saf. 2010 Jul; 9 (4): 659-66

Impact-Faktor: 2.496 (2009)

### III Fallberichte

1. Müller N, **Riedel M**, Erfurth A, Möller HJ: Immunoglobulin therapy in Gilles de la Tourette's syndrom. In: Nervenarzt, 1997, 68 (11), 914 - 916  
Impact-Faktor: 0.621
2. **Riedel M**, Straube A, Schwarz MJ, Wilske B, Müller N: Lyme disease presenting as Tourette's disorder. Lancet, 1998, 351, 418 – 419  
Impact-Faktor: 11.793
3. Strassnig M, **Riedel M**, Müller N: Electroconvulsive Therapy in a Patient with Tourette's Syndrome and Co-morbid Obsessive Compulsive Disorder. In: World J Biol Psychiatry, 2004, 5, 164 - 166  
Impact-Faktor: 2.888 (2005)
4. Dehning S, **Riedel M**, Müller N: Aripiprazol in a Patient Vulnerable to Side Effects. In: Am J Psychiatry, 2005, 162, 625  
Impact-Faktor: 8.286
5. Seemuller F, Volkmer E, Vogel T, Hummel T, Krauseneck T, **Riedel M**, Padberg F: Quetiapine as treatment for delirium during weaning from ventilation: a case report. J Clin Psychopharmacol. 2007 Oct;27(5):526-8  
Impactfactor: 3.878
6. Dehning S, **Riedel M**, Müller N. Father-to-son transmission of 6;17 translocation in Tourette's syndrome. Am J Psychiatry. 2008 Aug;165(8):1051-2  
Impactfactor: 10.545
7. Schennach-Wolff R, Stübner S, **Riedel M**, Müller N. Extensive elevation of creatine kinase with generic clozapine, but not with Leponex. Psychiatry Res. 2010 Mar 30; 176(1):93  
Impactfactor:2.373

### IV. Buchkapitel

1. Müller N, **Riedel M**, Schwarz MJ, Gruber R, Ackenheil M: Immunomodulatory effects of neuroleptics to the cytokine system and the cellular immune system in schizophrenia. In: G. Wieselmann (ed.) Current Update in Psychoimmunology, Springer Verlag Wien, NY, 1997, 57-67

2. Müller N, **Riedel M**, Schwarz MJ, Gruber R, Ackenheil M: Zelluläres System und Zytokinsystem Schizophrener: Immunmodulatorische Effekte antipsychotischer Therapie. In: H.-J. Möller (Hrsg) Schizophrenie – Moderne Konzepte zu Diagnostik, Pathogenese und Therapie, Springer Wien, NY, 1998, 143 – 153
3. Schwarz MJ, **Riedel M**, Ackenheil M, Müller N: Levels of Soluble Adhesion Molecule receptor in Schizophrenia: Relation to Psychopathology. In: N. Müller (Hrg) Psychiatry, Psychoneuroimmunology, and Viruses. Springer Verlag Wien, NY, 1999, 121 –130
4. Empl M, Sostak P, Brekner M, **Riedel M**, Müller N, Gruber R, Förderreuther S, Straube A: T cell subsets and expression of integrins in peripheral blood of patients with migraine and chronic tension type headache. In: N. Müller (Hrg) Psychiatry, Psychoneuroimmunology, and Viruses. Springer Verlag Wien, NY, 1999, 145 – 152
5. Müller N, **Riedel M**, Schaub A, Möller HJ: Kognitive Funktionen als Prognosekriterien des Krankheitsverlaufs bei schizophrenen Störungen. In: J. M. Fegert (Hrsg) Atypische Neuroleptika in der Jugendpsychiatrie. Schattauer Verlag, 1999, 207-218
6. Müller N, Froschmayr S, **Riedel M**, Möller HJ: Therapie mit atypischen Neuroleptika auf der Schizophrenie-Spezialstation einer Universitätsklinik – Eine Bestandsaufnahme. In: H.-J. Möller, N. Müller (Hrsg) Atypische Neuroleptika – Der Stellenwert in der Therapie schizophrener Psychosen. Springer Verlag Berlin, Heidelberg, NY, 1999, pp109-116
7. Müller N, Schaub A, Wolf B, Kaiser A, Gartenmeier A, **Riedel M**, Möller HJ: Atypische Neuroleptika und bewältigungsorientierte Therapie in einem integrierten Schizophrenie – Behandlungskonzept. In: B. Bandelow, E. Rüther (Hrsg) Therapie mit Neuroleptika – Qualitätsmanagement und Arzneimittelsicherheit. Steinkopff Verlag Darmstadt, 2000, 33 – 42
8. **Riedel M**, Schäfer U, Krampe K, Möller HJ, Müller N: Schützt Clozapin vor extrapyramidal-motorischen Nebenwirkungen klassischer Neuroleptika? In: D. Naber, F. Müller-Spahn (Hrsg.) Leponex: Pharmakologie und Klinik eines atypischen Neuroleptikums. Springer Verlag Berlin Heidelberg New York, 2001
9. Schwarz MJ, Müller N, **Riedel M**, Ackenheil M: Markers of Cellular and Humoral Immune Activity: A Th2 Shift in Schizophrenia? In: B. Sperner-Unterweger, W. W. Fleischhacker, W. P. Kaschka (Hrsg) Psychoneuroimmunology – Hypothesis and Current Research. Karger Basel, 2001, 61 – 65
10. Müller N, **Riedel M**, Ackenheil M, Schwarz MJ: Immune Function in Schizophrenia: The Role of Disease and Antipsychotic Medication. In: B. Sperner-Unterweger, W. W. Fleischhacker, W. P. Kaschka (Hrsg) Psychoneuroimmunology – Hypothesis and Current Research. Karger Basel, 2001, 75 – 86
11. **Riedel M**, Müller N, Möller HJ: Klinik Nefazodon. In P. Riederer, G. Laux, W. Pöldinger (Hrsg), Neuro-Psychopharmaka, Ein Therapie-Handbuch. Band 3: Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer. Springer, Wien NY, 2002, 249-348
12. **Riedel M**, Möller HJ: Schizophrene und schizophreniforme Störungen: In Schölmerich J: Medizinische Therapie in Klinik und Praxis: Springer 2003, 1302-1312

13. Müller N, **Riedel M**, Krampe K: Tics In: Jahn: Bewegungsstörungen bei psychischen Erkrankungen. Springer Berlin Heidelberg New York, 2004, 215-231
14. **Riedel M**, Strassnig M, Möller H-J, Müller N. Die Stellung der Depot-Neuroleptika aus heutiger Sicht. In: Möller H-J, Müller N (Hrsg.) Schizophrenie. Langzeitverlauf und Langzeittherapie. Springer, Wien, New York, 2004, 215-231
15. **Riedel M**, Strassnig M, Möller H-J, Müller N. Elektrokonvulsionstherapie bei Neuroleptika-Therapie-Refraktarität schizophrener Erkrankungen. In: Baghai T, Frey R, Kasper S, Möller H-J (Hrsg.) Elektrokonvulsionstherapie. Klinische und wissenschaftliche Aspekte. Springer Verlag, Wien, 2004, 428-443
16. Müller N, **Riedel M**, Scheppach C, Ulmschneider M, Ackenheil M, Möller H-J, Schwarz MJ. Ist eine antientzündliche Behandlung eine neue Therapieoption bei Schizophrenie? In: Möller H-J, Müller N (Hrsg.): Schizophrenie. Langzeitverlauf und Langzeittherapie. Springer, Wien, 2004, 203-213
17. Schwarz MJ, **Riedel M**, Dehning S, de Jonge S, Krönig H, Müller-Ahrends A, Neumeier K, Sikorski C, Spellmann I, Zill P, Ackenheil M, Müller N: Microarray- und immungenetische Untersuchungen bei Schizophrenie: In: Möller HJ, Müller N (Hrsg): Schizophrenie – Langzeitverlauf und Langzeittherapie: Springer, 2004, 73 – 96
18. Riedel M, Müller N: Affektive Psychosen. In: Wehling, Klinische Pharmakologie. Thieme Verlag, 2005, 463 – 474
19. Müller N, Riedel M: Organische psychische Störungen. In: Wehling (Hrsg), Klinische Pharmakologie. Thieme Verlag, 2005, 507 – 511
20. **Riedel M**, Möller HJ: Schizophrene und schizophreniforme Störungen: In Schölmerich J: Medizinische Therapie: Springer 2006, 1342-1351
21. **Riedel M**, Spellmann I: Quetiapin in der Behandlung der Negativsymptomatik. In: H.-J. Möller (Hrsg) Das Quetiapin-Dossier. Schattauer Verlag, 2005, 75 – 94
22. Müller N, Schwarz MJ, **Riedel M**: COX-2 Inhibition in Schizophrenia – Focus on Clinical Effects of Celecoxib Therapy and the Role of TNF- $\alpha$ . In: William W. Eaton, Ph.D.(Editor): Medical and Psychiatric Comorbidity - Over the Course of Life. American Psychiatric Publishing, Inc., 2005, 265 – 276
23. **Riedel M**, Möller HJ: Schizophrene und schizophreniforme Störungen: In Schölmerich J: Medizinische Therapie: Springer 2007, 1507-1517
24. Möller H.-J., Deister A., Schaub A., **Riedel M.**: Schizophrenie: In: Möller, Laux, Kapfhammer (Hrsg): Psychiatrie und Psychotherapie: Springer Verlag, 2007,
25. Möller H.-J., **Riedel M**: Side effect burden of antipsychotic medication. In: Schizophrenia – Biopsychosocial Approches and Current Challenges. Edited by Kasper S and Papadimitriou: informa healthcare, 2009
26. **Riedel M**, Spellmann I: Kognitive Störungen bei Schizophrenie und ihre Therapie. In: Schizophrenie – Zukunftsperspektiven in Klinik und Forschung. Hrsg.:Möller H.-J., Müller N. Springer 2009, S. 205 – 217



27. Bondy B, Spellmann I, Musil R, Zill P, Müller N, Möller H.-J., **Riedel M**: Die Bedeutung der Pharmakogenetik für die antipsychotische Therapie. In: Schizophrenie – Zukunftsperspektiven in Klinik und Forschung. Hrsg.:Möller H.-J., Müller N. Springer 2009, S. 219 – 228
28. Schwarz M.J., Musil R, Spellmann I, Opgen-Rhein M, Jurgeleit F, Sirch S, Sterz S, Zach J, **Riedel M**: Therapeutisches Drug-Monitoring neuerer atypischer Antipsychotika. In: Schizophrenie – Zukunftsperspektiven in Klinik und Forschung. Hrsg.:Möller H.-J., Müller N. Springer 2009, S. 229 – 241
29. Möller H.-J., Schaub A., **Riedel M.**: Schizophrene Psychosen: In: Möller, Laux, Kapfhammer (Hrsg): Psychiatrie Psychosomatik und Psychotherapie: Springer Verlag, 2010, S 215-324
30. **Riedel M.**, Seemüller F., Musil R., Spellmann I., Möller H.J., Schennach-Wolff R.: Early Improvement and Its Predictive Validity in First-Episode Schizophrenia Patients. In: M.S. Ritsner (ed.), Handbook of Schizophrenia Spectrum Disorders, Volume III, Therapeutic Approaches, Comorbidity, and Outcomes, Springer Verlag 2011, 93-108
31. Schennach-Wolff R., Seemüller F., Musil R., Spellmann I., Möller H.J., **Riedel M.**: Suicidality and Outcome in Schizophrenia Patients. In: M.S. Ritsner (ed.), Handbook of Schizophrenia Spectrum Disorders, Volume III, Therapeutic Approaches, Comorbidity, and Outcomes, Springer Verlag 2011, 365 – 382
32. **Riedel M**, Müller N, Severus E: Affektive Störungen. In: Wehling, Klinische Pharmakologie. Thieme Verlag, 2011, 474 – 487
33. Müller N Riedel M: Organische psychische Störungen. In: Wehling, Klinische Pharmakologie. Thieme Verlag, 2011, 519 – 524

Impactfactor Originalarbeiten mit Fallberichten gesamt: 613.613

Impactfactor Originalarbeiten mit Fallberichten als Erst- und Letztautor: 217.401

Impactfactor Übersichtsarbeiten gesamt: 25.584

Impactfactor Übersichtsarbeiten als Erst-und Letztautor: 13.69